PCRX: Pacira BioSciences, Inc. Stock

by  •  • Comments Off on PCRX: Pacira BioSciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 755.86
Enterprise Value ($M) 1,097.25
Book Value ($M) 749.58
Book Value / Share 16.23
Price / Book 1.01
NCAV ($M) -82.14
NCAV / Share -1.78
Price / NCAV -9.20

Profitability (mra)
Return on Invested Capital (ROIC) -0.07
Return on Assets (ROA) -0.06
Return on Equity (ROE) -0.11

Liquidity (mrq)
Quick Ratio 1.89
Current Ratio 2.25

Balance Sheet (mrq) ($M)
Current Assets 689.97
Assets 1,521.69
Liabilities 772.11
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 10.98 3.52
01-19 13G/A BlackRock, Inc. 17.50 11.90

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPO
2024-07-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT P
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2023 Or ☐ TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 64,993 493,887 13.16
2024-11-14 33,597 244,025 13.77
2024-11-13 64,352 503,832 12.77
2024-11-12 49,085 601,175 8.16
2024-11-11 46,651 412,608 11.31

(click for more detail)

Similar Companies
OVID – Ovid Therapeutics Inc. PASG – Passage Bio, Inc.
PBYI – Puma Biotechnology, Inc. PCVX – Vaxcyte, Inc.
PEPG – PepGen Inc.


Financial data and stock pages provided by
Fintel.io